---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-191859"
form_type: "8-K"
ticker: "VRCA"
cik: "0001660334"
company_name: "Verrica Pharmaceuticals Inc."
filed_at: "2023-07-24T23:59:59+00:00"
generated_at: "2026-06-13T04:16:07.407355+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Verrica FDA approves YCANTH for molluscum; secures up to $125M debt financing

## Summary
- YCANTH (cantharidin 0.7%) topical solution approved for molluscum contagiosum in patients 2+ years; first FDA-approved treatment for the indication.
- Phase 3 CAMP-1: 46% complete clearance vs 18% placebo (p<0.0001); CAMP-2: 54% vs 13% (p<0.0001).
- Non-binding term sheet for up to $125M debt facility; $50M available immediately at close, expected by end of week.
- Debt is 5-year term loan bearing SOFR + 8% (4% floor); warrant for $3.1M common stock at 10-day VWAP.
- Verrica plans commercial launch by September 2023; cash runway extended into Q1 2025 with $60M on hand plus $50M upfront.

## SEC filing metadata
- accession: 0001193125-23-191859
- form_type: 8-K
- ticker: VRCA
- cik: 0001660334
- company_name: Verrica Pharmaceuticals Inc.
- filed_at: 2023-07-24T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1660334/000119312523191859/0001193125-23-191859-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1660334/000119312523191859/d542791d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-191859
- JSON: https://secwatch.observer/filing/0001193125-23-191859.json
- Plain text: https://secwatch.observer/filing/0001193125-23-191859.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.